Efficacy and Safety of Cannabinoids for Neuropsychiatric Symptoms of Dementia: A Systematic Review with Meta-analysis.
| Journal | CNS drugs |
| Study Type | Randomized Trial |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Neuropsychiatric symptoms (NPS) are highly prevalent in persons with dementia and have been associated with adverse health outcomes. Neuropsychiatric symptoms can impose major physical, psychosocial, and financial burdens on caregivers while contributing to additional pressure on healthcare systems. Although atypical antipsychotics have received regulatory approval for treating specific NPS, such as agitation, their use in older adults has been linked to higher risks of mortality, cardiovascular events, and falls. Cannabinoids have emerged as promising pharmacological treatments for NPS in dementia, including agitation, anxiety, and depressive symptoms, owing to their behavior-modulating effects. The objective of this study was to provide a comprehensive assessment of the efficacy and safety of cannabinoids for NPS in dementia, which may help refine evidence-based guidelines for their use. We systematically reviewed studies from MEDLINE, Embase, PsycINFO, CINAHL, Cochrane Library, and
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
How common and burdensome are neuropsychiatric symptoms in dementia?
Very common. Neuropsychiatric symptoms are highly prevalent in people with dementia and have been associated with adverse health outcomes. They can also impose major physical, psychosocial and financial burdens on caregivers and add to the pressure on healthcare systems.
Atypical antipsychotics have received regulatory approval for specific neuropsychiatric symptoms such as agitation. However, their use in older adults has been linked to higher risks of mortality, cardiovascular events and falls, which the article presents as an important drawback of this existing treatment option.
Why are cannabinoids being studied for agitation and anxiety in dementia?
Cannabinoids have emerged as promising pharmacological treatments for neuropsychiatric symptoms in dementia, including agitation, anxiety and depressive symptoms. The article attributes this interest to their behavior-modulating effects, and it describes them as promising rather than as an established treatment.
What was this systematic review and meta-analysis designed to assess?
Its objective was a comprehensive assessment of both the efficacy and the safety of cannabinoids for neuropsychiatric symptoms in dementia, with the aim of helping refine evidence-based guidelines for their use. The authors systematically searched databases including MEDLINE, Embase, PsycINFO, CINAHL and the Cochrane Library. It was published in the journal CNS Drugs.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
